Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at European Society for Medical Oncology (ESMO) Congress 2021 September 27, 2021
Real-world management and patient perspectives on QOL with neuroendocrine tumours: An ANZ perspective July 27, 2021
